this is not an issue mate ata all as the randomisation covers this through equal distribution of those types of participants who were probably excluded from the study anyway as that’s back pain trials 101. Besides vas is the gold standard to what the fda have to use so again non issue.
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-97
-
- There are more pages in this discussion • 1,007 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
-0.035(2.43%) |
Mkt cap ! $1.627B | |||
| Open | High | Low | Value | Volume |
| $1.44 | $1.46 | $1.40 | $1.198M | 840.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 55208 | $1.41 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.41 | 3854 | 4 |
View Market Depth
| Last trade - 11.31am 15/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |